EFFECTS OF TUMOR-NECROSIS-FACTOR-ALPHA TREATMENT ON MORTALITY IN MURINE CYTOMEGALOVIRUS-INFECTED MICE

被引：12

作者：

ANDERSON, KP ^{[1
]}

LIE, YS ^{[1
]}

LOW, MAL ^{[1
]}

FENNIE, EH ^{[1
]}

机构：

[1] GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080

来源：

ANTIVIRAL RESEARCH | 1993年 / 21卷 / 04期

关键词：

MURINE CYTOMEGALOVIRUS; TUMOR NECROSIS FACTOR-ALPHA; INTERFERON-GAMMA; MOUSE; MORTALITY;

D O I：

10.1016/0166-3542(93)90012-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effects of treatment with recombinant DNA-derived Tumor Necrosis Factor-alpha (TNF-alpha) in a murine model of cytomegalovirus infection were investigated. Treatment of 3-week-old Swiss Webster mice with murine TNF-alpha prior to infection with murine cytomegalovirus (MCMV) had no demonstrable effect on mortality. However, if mice were treated prior to infection with a combination of murine IFN-gamma and murine TNF-alpha, the dose of IFN-gamma required to achieve significant reduction in mortality was reduced by a factor > 10. In contrast to the beneficial effects of prophylactic TNF-alpha treatment in combination with IFN-gamma, TNF-alpha treatment of mice after MCMV infection resulted in increased mortality. The increased mortality occurred when non-lethal doses of TNF-alpha were used and required virus replication. The effects of TNF-alpha treatment on mortality in MCMV-infected mice were not predicted from cell culture experiments which evaluated the effects of TNF-alpha treatment on MCMV replication in primary mouse embryo fibroblasts.

引用

页码：343 / 355

页数：13

共 33 条

[1]

AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345

[2]

ALFORD C A, 1990, P1981

[3]

ANDERSON KP, 1988, J IMMUNOL, V140, P3599

[4] ACYCLOVIR IN IMMUNOCOMPROMISED PATIENTS WITH CYTOMEGALOVIRUS DISEASE - A CONTROLLED TRIAL AT ONE INSTITUTION [J].

BALFOUR, HH ;

BEAN, B ;

MITCHELL, CD ;

SACHS, GW ;

BOEN, JR ;

EDELMAN, CK .

AMERICAN JOURNAL OF MEDICINE, 1982, 73 (1A) :241-248

[5]

BURTON LE, 1984, BIOL INTERFERON SYST, P403

[6] CONTROLLED CLINICAL-TRIAL OF PROPHYLACTIC HUMAN-LEUKOCYTE INTERFERON IN RENAL-TRANSPLANTATION - EFFECTS ON CYTOMEGALO-VIRUS AND HERPES-SIMPLEX VIRUS-INFECTIONS [J].

CHEESEMAN, SH ;

RUBIN, RH ;

STEWART, JA ;

TOLKOFFRUBIN, NE ;

COSIMI, AB ;

CANTELL, K ;

GILBERT, J ;

WINKLE, S ;

HERRIN, JT ;

BLACK, PH ;

RUSSELL, PS ;

HIRSCH, MS .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (24) :1345-1349

[7] EFFECTS OF CYTOKINES ON VASCULAR ENDOTHELIUM - THEIR ROLE IN VASCULAR AND IMMUNE INJURY [J].

COTRAN, RS ;

POBER, JS .

KIDNEY INTERNATIONAL, 1989, 35 (04) :969-975

[8]

CZARNIECKI CW, 1985, J INTERFERON RES, V6, P29

[9] TUMOR NECROSIS FACTOR A ACTIVATES HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 THROUGH INDUCTION OF NUCLEAR FACTOR BINDING TO THE NF-KAPPA-B SITES IN THE LONG TERMINAL REPEAT [J].

DUH, EJ ;

MAURY, WJ ;

FOLKS, TM ;

FAUCI, AS ;

RABSON, AB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (15) :5974-5978

[10] REDUCED MORTALITY IN MURINE CYTOMEGALO-VIRUS INFECTED MICE FOLLOWING PROPHYLACTIC MURINE INTERFERON-GAMMA TREATMENT [J].

FENNIE, EH ;

LIE, YS ;

LOW, MAL ;

GRIBLING, P ;

ANDERSON, KP .

ANTIVIRAL RESEARCH, 1988, 10 (1-3) :27-39

← 1 2 3 4 →